Introduction
The reported prevalence of liver biochemical abnormalities in patients with untreated thyrotoxicosis varies widely, ranging from 15% to 79%. [1] [2] [3] [4] [5] [6] Processes contributing to biochemical hepatic abnormalities include excess thyroid hormone, elevated thyroid receptor antibody (TRAb) titres in Graves' disease, relative hepatic anoxia, apoptosis and increased susceptibility to oxidative stress. 2, 5, [7] [8] [9] [10] [11] [12] Other factors contributing to hepatic abnormalities in individuals with untreated hyperthyroidism include heart failure, effects of antithyroid drugs, and concomitant liver disease. 13 Although the pattern of biochemical hepatic abnormalities and hepatic injury in the setting of hyperthyroidism is variable in character and severity, 14 it appears to be predominantly hepatitic, 3,4,14-17 with a few case reports demonstrating a cholestatic pattern. [18] [19] [20] The first report of hepatic necrosis in a patient with thyrotoxicosis occurred in 1874. 21 In 1967, liver biopsies of 23 hyperthyroid patients showed that 90% had fatty change. 22 Other changes included megamitochondria with irregular volume and increased membrane volume. 23 Further studies demonstrated that the degree of biochemical hyperthyroxinaemia does not correlate with cellular and ultrastructural abnormalities. 22, 23 Liver abnormalities were mostly hepatitic with predominantly serum aspartate transaminotransferase (AST), alanine aminotransferase (ALT), and bilirubin elevations, with some increased serum alkaline phosphatase (AP) and gamma-glutamyltransferase (GGT) concentrations. 3,4,14-16 However, AP elevations may not necessarily originate from the liver and can represent elevations in the bone isoenzyme. 3 Other reports of untreated thyrotoxicosis also have reported a cholestatic pattern with a predominant AP elevation and/or biopsy-proven cholestasis. [18] [19] [20] There is limited understanding regarding the patterns of biochemical liver abnormality changes that occur upon treatment Correspondence: Angela M. Leung, Division of Endocrinology, Diabetes, and Hypertension, UCLA David Geffen School of Medicine, 11301 Wilshire Blvd (111D), Los Angeles, CA, 90073, USA. Tel.: 310-478-3711 x49088; E-mail: amleung@mednet.ucla.edu of hyperthyroidism. The relationships between use of anti-thyroid drugs and biochemical liver abnormalities have been described in a few small series, [24] [25] [26] [27] [28] while those for other therapies in hyperthyroidism (radioactive iodine and surgery) have been rarely described. 13, 15, [29] [30] [31] This retrospective study investigates the patterns of liver biochemical abnormalities in patients at our institution with a new diagnosis of thyrotoxicosis.
Materials and methods
We 
Patients using medications that may affect liver biochemistries or thyroid function tests (statins, azole antifungals, isoniazid, valproic acid and amiodarone) or patients with pre-existing liver conditions (fatty liver, alcoholic/nonalcoholic hepatitis, hepatitis B and C, cirrhosis, cholangitis) were excluded. Differences in the frequencies of biochemical liver abnormalities were assessed using Chi-square tests. Cox regression models were used to determine significant predictors of a biochemical liver abnormality. P values <0Á05 were considered significant. The study was approved by the UCLA Institutional Review Board (IRB).
Results
There were 1514 patients (mean AE SD age, 60Á0 AE 19Á1 years; 77% women; 60% White) with a new diagnosis of thyrotoxicosis and available biochemical liver test(s) within 6 months of the onset of thyrotoxicosis during the study period (Table 1) . Age, gender, race and ethnicity were self-reported, as recorded in the medical record.
The overall incidence of any biochemical liver test abnormality within 6 months of thyrotoxicosis was 39%. Of the 811 patients whose serum TSH level was below the detection limit (≤0Á02 mIU/l), 45% had an abnormal liver biochemical test (13% AST, 13% ALT, 35% AP, 2% GGT, 9% total bilirubin, 6% conjugated bilirubin). In comparison, of the 697 patients whose serum TSH level was above the detection limit (> 0Á02 mIU/L), 33% had an abnormal liver biochemical test (18% AST, 14% ALT, 22% AP, 2% GGT, 15% total bilirubin, and 12% conjugated bilirubin; Fig. 1 ).
Serum TSH concentration ≤0Á02 mIU/l, male gender, and African-American race were significant positive predictors for a biochemical liver abnormality (Table 2 ). Serum TSH concentration ≤0Á02 mIU/l, male gender, and African-American race were significant positive predictors for abnormal AP; non-Hispanic or Latino and other ethnicities were significant negative predictors for abnormal AP (Table 3 ). There were no significant positive predictors for abnormal serum GGT concentrations.
Serum TSH concentration ≤0Á02 mIU/l and non-Hispanic or Latino and other ethnicities were significant negative predictors for abnormal total bilirubin and abnormal conjugated bilirubin (Tables 4 and 5) ; male gender was a significant positive predictor for abnormal total conjugated bilirubin (Table 4) ; male gender and African-American race were significant positive predictors for abnormal conjugated bilirubin (Table 5) . Male gender and African-American race were significant positive predictors for abnormal serum ALT and AST concentrations (Tables 6 and 7) ; not Hispanic or Latino ethnicity was a significant negative predictor for abnormal serum AST concentration (Table 7) .
Discussion
In this retrospective cohort study of patients at a large, urban academic medical centre, there was a 39% incidence of liver biochemical abnormalities within 6 months of a new diagnosis of thyrotoxicosis. Increased risks were observed in those with an initial serum TSH concentration of ≤0Á02 mIU/l, in men, and in African-Americans.
Although there are many previous studies that have linked thyrotoxicosis with liver biochemical abnormalities, [1] [2] [3] [4] [5] [6] few have investigated whether the severity of thyrotoxicosis affects the presence of abnormal liver function tests (LFTs). The present findings indicate that among patients with the diagnosis of thyrotoxicosis, serum TSH concentration ≤0Á02 mIU/l, as compared to those with a serum TSH >0Á02 mIU/l, is a significant distinction as a predictor of any LFT abnormality, as well as for specific LFT abnormalities, including AP, total bilirubin, and conjugated bilirubin. However, this distinction does not seem to be significant in analyses of abnormal serum ALT, AST, or GGT concentrations. Unlike previous studies in which the prevalence of liver biochemical abnormalities were not significantly affected by gender, 7 this study consistently indicates that male gender is a significant positive predictor for LFT abnormalities, including serum AP, total bilirubin, conjugated bilirubin, ALT, and AST concentrations. Additionally, few studies in the past have investigated race and/or ethnicity as predictors of abnormal biochemical tests in hyperthyroidism. The African-American race is not known to be a predictor for LFT abnormalities independent of hyperthyroidism. In this cohort, African-American race is found to be a significant positive predictor for abnormal serum AP, conjugated bilirubin, ALT, and AST concentrations. This may be explained by increased severity of thyrotoxicosis compared to other racial groups, or the presence of comorbidities with a higher prevalence in African-Americans that affect thyroid and/ or liver function. Limitations to the study include the low frequency of positive serum thyroid autoantibodies in our cohort, which may be an important covariate for the development of liver function test abnormalities. Rather than investigating the effect of thyroid medications on liver biochemical patterns, [24] [25] [26] [27] [28] we have excluded patients who were using propylthiouracil or methimazole, as well as any other drugs that may affect liver metabolism, from this patient cohort. The study focused on predictors of incident abnormal LFTs, rather than changes in abnormal LFTs after treatment for thyrotoxicosis. Although we excluded patients who used medications which may affect liver biochemistries or thyroid function tests, as well as patients with pre-existing liver conditions, other possible conditions that may affect liver and thyroid function, such as cardiac disease, remain as potential confounding variables in this study. Finally, the study did not assess the time course of resolution of the abnormal liver biochemical tests.
The study utilizes a large cohort of patients seen at a large, academic, urban US medical centre to provide further understanding of the patients who were evaluated for liver biochemical abnormalities upon the onset of a new diagnosis of thyrotoxicosis. In the patient populations in which increased risks of abnormal liver biochemical tests were found (initial serum TSH concentration ≤0Á02 mIU/l, men, AfricanAmericans), clinicians may consider monitoring liver function at an earlier time (1-3 months immediately after initial diagnosis of thyrotoxicosis), to prevent progression to liver disease. Further research is needed to explore the reasons for increased risk of liver biochemical abnormalities in certain populations, the time course to resolution, and guidance for use of antithyroidal therapy in such patients. 
